US Pharma MarketingThe post D&D Pharmatechs’ zabopegdutide shows rapid, weight-loss-independent MASH benefit appeared first on Clinical Trials Arena.
D&D Pharmatechs’ zabopegdutide shows rapid, weight-loss-independent MASH benefit
D&D Pharmaceuticals has recently published new data from its ongoing Phase II trial of zabopegdutide in F1-F3 MASH and MASLD patients. The post D&D Pharmatechs’ zabopegdutide shows rapid, weight-loss-independent MASH benefit appeared first on Clinical Trials Arena .
D&D Pharmaceuticals has recently published new data from its ongoing Phase II trial of zabopegdutide in F1-F3 MASH and MASLD patients.
Source: Clinical Trials Arena